Survodutide
GLP-1 + glucagon dual agonist · GLP-1 class · sc weekly · Boehringer Ingelheim
Top dose
4.8 mg
HbA1c reduction
-1.70%
at week 16 · efficacy
AE discontinuation
12.0%
Status
phase 2
Pivotal trial
- Trial
- Phase 2 T2D (NCT04153929)
- Indication
- type 2 diabetes
- Duration
- 16 weeks
- ClinicalTrials.gov
- NCT04153929
- Sponsor
- Boehringer Ingelheim
Notes
Phase 2 T2D dose-finding (NCT04153929): survodutide reduced HbA1c ~-1.7% at the higher doses. No peer-reviewed standalone T2D efficacy paper - Boehringer has prioritised MASH (SYNCHRONIZE-MASLD, Phase 3) and obesity; the T2D number here is the trial-registry / conference read, not a journal publication.